Shifting human behaviors to more sustainable outcomes can be informed by the targets we set for ourselves. Quality, not quantity, is the promise
Andrew Milligan is an independent economist and investment consultant. He is a Board member of the Asia Scotland Institute, an adviser to the Health Foundation, to Balmoral Asset Management and to the Educational Institute of Scotland, and a Fellow of the Society of Professional Economists. From 2000-20, Andrew was the chief market strategist for the global fund manager Aberdeen Standard Investments.
After graduating from Bristol University, Andrew started in H.M. Treasury where he specialised in the IMF and World Bank’s handling of the Latin American debt crisis. He then worked in turn for Lloyds Bank, the broker Smith New Court, and New Japan Securities as an international economist. In 1995 he entered the asset management industry, becoming Head of Economic Research and Business Risk for Aviva Investors. In 2000 he moved to Edinburgh to work as the Head of Global Strategy for Standard Life Investments, in charge of a team covering economic and market research, tactical and strategic asset allocation decisions, client advice and communications for retail and institutional clients globally.
After its merger with Aberdeen Asset Management to form Aberdeen Standard Investments, the company became the second largest active fund manager in Europe with over 30 offices across the major financial centres. Andrew is well known as a public speaker while his writing, commentary and interviews have appeared in all the mainstream media.
For long periods of economic history, societies have built walls to defend themselves, relying on local suppliers to a domestic marketplace.
The long run is a forecaster’s biggest challenge. But it yields substantial rewards, among them recognition of future challenges and possible
The pandemic and its economic shockwaves are fundamentally re-ordering world affairs. Look no further than Europe.
Equity markets are waxing and waning on day-to-day news. Are earnings reports, new infection rates, vaccine development or hints about further